Atrial Fibrillation Market Size, Share, Trends, Forecast Report 2030

 Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke - an estimated 15% of all strokes are caused by AF, and it accounts for one-third of strokes in individuals aged 65 years or older.

DelveInsight's "Atrial Fibrillation - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atrial Fibrillation market report provides current treatment practices, emerging drugs, Atrial Fibrillation market share of the individual therapies, current and forecasted Atrial Fibrillation market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Atrial Fibrillation treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

Request for sample pages: https://www.delveinsight.com/sample-request/atrial-fibrillation-market

Atrial Fibrillation Disease Understanding and Treatment Algorithm

There are three primary forms of AF that have been categorized with regards to duration of episode. The first type is the intermittent or paroxysmal AF, which occurs spontaneously and generally resolves by itself or with treatment within 7 days. Persistent AF is the sustained abnormal heart rhythm for more than 7 days even with treatment or direct current cardioversion, while permanent AF occurs when all means of treatment to restore normal heart rhythm have failed.

The most common type of AF is the paroxysmal AF, which accounts for the maximum prevalent cases while the other types of AF are persistent and permanent.

The DelveInsight Atrial Fibrillation market report gives a thorough understanding of the Atrial Fibrillation by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Atrial Fibrillation. 

Treatment 

It covers the details of conventional and current medical therapies available in the Atrial Fibrillation market for the treatment of the condition. It also provides Atrial Fibrillation treatment algorithms and guidelines in the United States, Europe, and Japan. 

Atrial Fibrillation Epidemiology  

The Atrial Fibrillation epidemiology division provide insights about historical and current Atrial Fibrillation patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Atrial Fibrillation epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 

Country Wise- Atrial Fibrillation Epidemiology 

The epidemiology segment also provides the Atrial Fibrillation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Download useful Epidemiology insights of the report: https://www.delveinsight.com/report-store/atrial-fibrillation-epidemiology-forecast

Atrial Fibrillation Drug Chapters

Key players, such as Bristol-Myers Squibb, ARCA Biopharma, Omeicos Therapeutics GmbH, and many others are developing therapies for the treatment of patients with AFI. Gencaro (ARCA biopharma), Apixaban (Bristol-Myers Squibb), along with several other compelling options in the clinical trials are expected to increase the market size of AF in the upcoming years. A major upcoming player, ARCA Biopharma, has recently submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) to facilitate the development of Gencaro as a genetically-targeted treatment for heart failure (HF) patients at risk for Atrial Fibrillation.

Drug chapter segment of the Atrial Fibrillation report encloses the detailed analysis of Atrial Fibrillation marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atrial Fibrillation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs 

The report provides the details of the marketed product available for Atrial Fibrillation treatment. 

Atrial Fibrillation Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Atrial Fibrillation treatment. 

View pipeline insights of the report: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight

Atrial Fibrillation Market Outlook

Owing to the complexity of Atrial Fibrillation (AF), and the broad range of symptoms and comorbidities AF patients present, a number of pharmacological strategies are used to treat AF. Current medical practice focuses on the use of drugs to either establish normal sinus rhythm or to control heart rates in AF patients. The treatment mainly depends on the class of AF, the age of the patient, the presence of several comorbidities, such as heart disease, and the estimated risk of stroke.

A wide range of treatments are available for the management of AF, including pharmacological therapy, surgical procedures, and medical devices. Pharmacological treatment for AF consists of two elements: treatment for control of the ventricular rate or rhythm, and antithrombotic agents to prevent stroke.

The Atrial Fibrillation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Atrial Fibrillation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Atrial Fibrillation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Atrial Fibrillation market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Atrial Fibrillation market in 7MM.

The United States Market Outlook

This section provides the total Atrial Fibrillation market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Atrial Fibrillation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook 

The total Atrial Fibrillation market size and market size by therapies in Japan is also mentioned. 

View market insights of the report: https://www.delveinsight.com/report-store/atrial-fibrillation-market

 

 

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more